

DAFTAR PUSTAKA

- Ahmed S.S., Laila T.R., Begum H.A., Moniruzzaman, 2013, Proteinuria in Chronic Kidney Disease and its Management, *Medicine Today* 25 (1):37-41
- American Diabetes Association, 2009, Diagnosis and Classification of Diabetes Mellitus, *Diabetes Care*. 2009 Jan; 32(Suppl 1): S62–S67.
- Arsana P.M., Rosandi R., Manaf A., Budhiarta A.A.G., Permana H., Sucipta K.W., Lindarto D., Adi S., Pramono B., Harbuwono D.S., Shahab A., Sugiarto, Karimi J., Purnomo L.B., Yuwono A., Suhartono T., 2015, *Panduan Pengelolaan Dislipidemia di Indonesia 2015*, P.B. Perkeni.
- Aziz K.M.A., 2012, Targeting ldl dyslipidemia for controlling progression of nephropathy in diabetic population: A cross sectional analytical study, *Journal of the Dow University of Health Sciences Karachi* 6 (1): 7-11
- Chapman M.J., Ginsberg H.N., Amarenco P., Andreotti F., Borén J., Catapano A.L., Descamps O.S., Fisher E., Kovanen P.T., Kuivenhoven J.A., Lesnik P., Masana L., Nordestgaard B.G., Ray K.K., Reiner Z., Taskinen M.R., Tokgözoglu L., Tybjærg-Hansen A., Watts G.F., 2011, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, *Eur Heart J.* 32(11):1345-61.
- Cheng H., Harris R.C., 2014, Renal endothelial dysfunction in diabetic nephropathy, *Cardiovasc Hematol Disord Drug Targets*. 14(1): 22–33.
- Cravedi P., Remuzzi G., 2013, Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease, *Br J Clin Pharmacol* 76(4):516-23.
- Dahlan M.S., 2009, *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*, Salemba Medika, Jakarta.
- Eiselein L., Wilson D.W., Lame M.W., Rutledge J.C., 2007, Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis, *Am J Physiol Heart Circ Physiol* 292(6):H2745–53.
- Eknayan G., Lameire N., Eckardt K-U., Kasiske B.L., Wheeler D.C., 2013, KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease, *Kidney International Supplements*.
- Guyton, A. C., Hall, J. E., 2014. *Buku Ajar Fisiologi Kedokteran*. Edisi 12.
- Hammad S.M., Hazen-Martin D.J., Sohn M., Eldridge L., Powell-Braxton L., Won W., 2003, Nephropathy in a hypercholesterolemic mouse model with streptozotocin-induced diabetes, *Kidney Blood Press Res.* 26(5-6):351–61

<http://www.kidney-cares.org/pkd-treatment/351.html>, diakes pada tanggal 2 November 2017.

Ishigaki N., Yamamoto T., Shimizu Y., Kobayashi K., Yatoh S., Sone H., 2007,. Involvement of glomerular SREBP-1c in diabetic nephropathy, *Biochem Biophys Res Commun* 364(3):502–8.

Isselbacher K.J., Braunwald E., Wilson J.D., 2013, Harrison Prinsip-Prinsip Ilmu, Jakarta : EGC, 1022

Jisieike-Onuigbo N.N., Unuigbe E.I., Oguejiofor C.O., 2011, Dyslipidemias in type 2 diabetes mellitus patients in Nnewi South-East Nigeria, *Ann Afr Med.* 10(4):285-289.

Kalaitzidis A.R., Bakris G., 2009, Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road, *The journal of clinical hypertension* 11(11):636-646

Kalbe, 2012, Efek pemberian bezafibrate terhadap metabolisme lemak dan glukosa pada pasien dislipidemia dengan diabetes, *Cermin Dunia Kedokteran* 39(8):617.

Kuwabara T., Mori K., Mukoyama M., Kasahara M., Yokoi H., Saito Y., 2012, Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice, *Diabetologia* 55(8):2256–66.

Lerma E.V., Batuman V., 2014, Diabetes and Kidney Disease, Springer, New York.

Lim A.K.H., 2014, Diabetic nephropathy – complications and treatment, *Int J Nephrol Renovasc Dis.* 7: 361–381.

López-Novoa J.M., Rodríguez-Peña A.B., Ortiz A., Martínez-Salgado C., Hernández F.J.L., 2011, Etiopathology of chronic tubular, glomerular and renovascular nephropathies: Clinical implications, *J. Transl Med.* 9: 13.

Mahan K., Escott-Stump S., Raymond J.L., 2012, *Krause Food and The Nutrition Care Process*, 13 ed. Elsevier.

Mega C., Teixeira-de-Lemos E., Fernandes R., Reis F. 2017, Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes, *J Diabetes Res.* 2017: 5164292.

Menon M.C., Chuang P.Y., He C.J., 2012, The glomerular filtration barrier: components and crosstalk, *International Journal of Nephrology*:1-9.

Mullins L.J., Conway B.R., Menzies R.I., Denby L., Mullins J.J., 2016, Renal disease pathophysiology and treatment: contributions from the rat, *Disease Models & Mechanisms* 9:1419-1433

Nosadini R., Tonolo G., 2011, Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes, *Nutr Metab Cardiovasc Dis.* 21(2):79–85.

Ozsoy R.C., van Leuven S., Kastelein J.J., Arisz L., Koopman M.G., 2006, The dyslipidemia of chronic renal disease: effects of statin therapy, *Curr Opin Lipidol* 17(6):659-66.

PERKENI, 2011, Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia.

Pramono L.A., 2009, Dislipidemia, *Journal medika*.

Rutledge J.C., Ng K.F., Aung H.H., Wilson D.W., 2010, Role of triglyceride-rich lipoproteins in diabetic nephropathy, *Nat Rev Nephrol* 6(6):361–70.

Sastroasmoro S., 2011, *Dasar-Dasar Metodologi Penelitian Klinis Edisi 4*, CV Sagung Seto, Jakarta.

Satirapoj B., Adler S.G., 2014, Comprehensive approach to diabetic nephropathy, *Kidney Res Clin Pract.* 33(3): 121–131.

Schofield J.D., Liu Y., Rao-Balakrishna P., Malik R.A., Soran H., 2016, Diabetes Dyslipidemia, *Diabetes Therapy* 7(2):203-219.

Setiati S., Alwi I., Sudoyo A.W., Stiyohadi B., Syam A.F., 2014, *Buku Ajar Ilmu Penyakit Dalam Jilid II (ed) VI*, InternaPublishing, Jakarta.

Siswardana S.R., 2011, Manajemen Hipertensi dengan Penyulit Proteinuria, *Cermin Dunia Kedokteran* 182:7-11.

Tjokroprawiro P.B., Setiawan C., Effendi D., Santoso, Soegiarto G., 2015, Buku Ajar Ilmu Penyakit Dalam: Fakultas Kedokteran Universitas Airlangga Rumah Sakit Pendidikan Dr. Soetomo Surabaya (2th ed.), Airlangga University Press, Surabaya.

Trevisan R., Dodesini A.R., Lepore G., 2006, Lipids and renal disease. *J Am Soc Nephrol* 17(4 Suppl 2):S145-7.

van den Brand J.A.J.G., 2016, Diabetes mellitus as a cause of end-stage renal disease in Europe: signs of improvement, *Clin Kidney J.* 9(3): 454–456.

Vaziri N.D., Liang K., Park S., 2003, Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis, *Kidney Int.* 63(5):1756-63.

